Homology Medicines
A genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.
Launch date
Employees
Market cap
€2.7m
Enterprise valuation
(€71m) (Public information from Mar 2024)
Share price
$47.17 FIXX
Lexington Kentucky (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 2.7m | 34.0m | 3.2m | 1.2m | 1.0m | 2.0m | - |
| % growth | 62 % | 1157 % | (91 %) | (64 %) | (13 %) | 100 % | - |
| EBITDA | (122m) | (87.6m) | (263m) | (91.0m) | - | - | - |
| % EBITDA margin | (4526 %) | (258 %) | (8206 %) | (7869 %) | - | - | - |
| Profit | (129m) | (95.8m) | (5.0m) | (113m) | (49.5m) | (73.1m) | (104m) |
| % profit margin | (4763 %) | (282 %) | (156 %) | (9772 %) | (4951 %) | (3655 %) | - |
| EV / revenue | 129.5x | 1.5x | -32.0x | 46.3x | 462.5x | 140.8x | - |
| EV / EBITDA | -2.9x | -0.6x | 0.4x | -0.6x | - | - | - |
| R&D budget | 100m | 93.1m | 98.4m | 62.0m | - | - | - |
| R&D % of revenue | 3715 % | 274 % | 3066 % | 5363 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
$43.5m | Series A | ||
$83.5m | Series B | ||
| N/A | N/A | IPO | |
$60.0m | Post IPO Equity | ||
* | N/A | Acquisition | |
| Total Funding | €115m | ||
